Publications by authors named "Hetal S Randeria"
Article Synopsis
- Bruton tyrosine kinase (BTK) is important for treating B-cell cancers, but existing covalent inhibitors have issues with side effects and resistance mutations.
- Pirtobrutinib is a new, selective, noncovalent BTK inhibitor that effectively targets BTK and its mutations without the same drawbacks as current treatments.
- Preclinical studies show that pirtobrutinib not only inhibits B-cell lymphoma growth and signaling but also demonstrates improved selectivity and stability, leading to Phase 3 clinical trials for various B-cell malignancies.
